Be Bio Announces New Preclinical Data Demonstrating its Novel Engineered B Cell Medicine (BCM), BE-1

BE-101 is Company’s Lead Program in Hemophilia B; IND Filing Anticipated in Mid-2024Be Bio Appoints Glenn Pierce, M.D., Ph.D., Hemophilia Physician-Researcher and Advocate, to its Scientific Advisory BoardPreclinical Study Findings Shared in Oral Presentation During 65th Annual Meeting of the American Society of Hem...

Related Keywords

San Diego , California , United States , American , Richarda Morgan , David Rawlings , Richard James , Joanne Smith Farrell , Bristol Myers Squibb , Us Department Of Health , Hemophiliab National Bleeding Disorders Foundation , Drug Administration , Longwood Fund , Human Services , Seattle Children Research Institute , American Society Of Hematology , Us Centers For Disease , Linkedin , Blood Products Advisory Committee , Committee On Blood Safety , Atlas Venture , Oral Presentation At American Society Of Hematology , Company Lead Program In Hemophilia , World Federation Of Hemophilia , Be Biopharma Inc , Meeting Of The American Society Hematology , Lead Program , Bio Appoints Glenn Pierce , Hemophilia Physician Researcher , Scientific Advisory , Study Findings Shared , Oral Presentation During , Annual Meeting , American Society , Engineeredb Cell Medicines , Glenn Pierce , Investigational New Drug , Scientific Advisory Board , World Federation , Vice President Medical , States Board , Scientific Advisory Council , National Bleeding Disorders , Blood Safety , Sustained Levels , Presentation Session , Novel Approaches , Chief Scientific Officer , New Class , Seattle Children , Alta Partners , Takeda Ventures , Research Institute , Disease Control , Accessed November , Bleeding Disorders ,